Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Medical Research

Background:

• Triple-negative breast cancer (TNBC) presents a poorer prognosis than other subtypes.
• Bevacizumab, an angiogenesis inhibitor, offers palliative benefits for TNBC and other breast cancer subtypes.
• PARP inhibitors are emerging as targeted treatments for hereditary and TNBC.

Purpose of the Study:

• To highlight the prognostic challenges in triple-negative breast cancer.
• To discuss the efficacy of bevacizumab and PARP inhibitors in TNBC treatment.
• To emphasize the importance of evaluating tumor phenotype changes from primary to metastatic sites in clinical trial design.

Main Methods:

• Review of current literature on breast cancer subtypes and targeted therapies.
• Analysis of treatment outcomes for bevacizumab and PARP inhibitors.
• Discussion of phenotypic shifts between primary tumors and metastases.

Main Results:

• Bevacizumab demonstrates efficacy in palliative treatment across breast cancer subtypes, including TNBC.
• PARP inhibitors are a key development for hereditary and TNBC.
• Significant and clinically relevant phenotype changes occur between primary tumors and metastases.

Conclusions:

• Modern clinical trials for targeted agents in metastatic breast cancer must include assessment of tumor phenotype.
• Confirming the presence of therapeutic targets in metastatic lesions is crucial for treatment efficacy.
• Tailoring treatment strategies based on metastatic phenotype is essential for improving patient outcomes.